Related Experiment Videos
Enzyme immunoassay for erythrocyte aldose reductase
C Nishimura1, Y Hamada, T Tachikawa
1Department of Pediatric Pharmacology, National Children's Medical Research Center, Tokyo, Japan.
Clinical Chemistry
|June 1, 1994
Summary
This study developed a new assay to measure erythrocyte aldose reductase levels. The assay can help optimize aldose reductase inhibitor treatments for diabetic complications.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Enzymology
Background:
- Aldose reductase is implicated in diabetic complications.
- Accurate measurement of erythrocyte aldose reductase is crucial for therapeutic monitoring.
Purpose of the Study:
- To develop and validate a novel immunoassay for quantifying human erythrocyte aldose reductase.
- To assess the clinical utility of this assay in distinguishing enzyme levels between sexes and age groups.
Main Methods:
- A two-site immunoassay utilizing monoclonal and polyclonal antibodies against recombinant human aldose reductase.
- Assay validation included limit of detection, analytical recovery, and precision (CVs).
- Enzyme content was correlated with isolated aldose reductase activity in erythrocyte preparations.
Main Results:
- The immunoassay demonstrated a low limit of detection (< 0.05 microgram/L) and high analytical recovery (101-106%).
- Intra-assay and inter-assay coefficients of variation (CVs) were 3.7% and 4.8%, respectively.
- Erythrocyte aldose reductase levels were significantly higher in women than in men (P < 0.001), with no age correlation.
Conclusions:
- The developed immunoassay is reliable and sensitive for measuring erythrocyte aldose reductase.
- This assay provides valuable clinical insights for optimizing aldose reductase inhibitor therapy.
- The findings suggest potential sex-based differences in aldose reductase levels relevant to diabetic complication management.